<seo title="Regeneron" metakeywords="regeneron biopharmaceutical,regeneron medicines developed,regeneron medicines,conclusion regeneron biopharmaceutical" metadescription="Regeneron is a biopharmaceutical company that specializes in the development, manufacture, and commercialization of medicines for the treatment of serious medical conditions." />
===Introduction to Regeneron===

Regeneron is a biopharmaceutical company that specializes in the development, manufacture, and commercialization of medicines for the treatment of serious medical conditions. Founded in 1988, Regeneron has grown to become one of the world’s leading biopharmaceutical companies, with a portfolio of more than 20 approved medicines and a pipeline of more than 40 investigational medicines. Regeneron’s medicines are used to treat a wide range of diseases, including cancer, cardiovascular disease, eye diseases, and inflammatory and autoimmune diseases. Regeneron is headquartered in Tarrytown, New York, and has operations in the United States, Europe, and Asia.
===History of Regeneron===

Regeneron was founded in 1988 by Leonard S. Schleifer, , PhD, and George  Yancopoulos, , PhD. The two scientists had a shared vision of creating a biopharmaceutical company that would develop innovative medicines to treat serious medical conditions. Since its founding, Regeneron has grown to become one of the world’s leading biopharmaceutical companies.

Regeneron has made significant advances in the development of medicines for the treatment of serious medical conditions. In 2011, Regeneron launched its first approved medicine, EYLEA® (aflibercept) Injection, for the treatment of wet age-related macular degeneration. Since then, Regeneron has launched several additional medicines, including DUPIXENT® (dupilumab) Injection for the treatment of atopic dermatitis, Praluent® (alirocumab) Injection for the treatment of high cholesterol, and Libtayo® (cemiplimab-rwlc) Injection for the treatment of cutaneous squamous cell carcinoma.
===Business Model of Regeneron===

Regeneron’s business model is focused on the development, manufacture, and commercialization of medicines for the treatment of serious medical conditions. Regeneron’s medicines are developed through a combination of internal research and development and collaborations with external partners. Regeneron’s medicines are manufactured in its own facilities and through collaborations with external partners. Regeneron’s medicines are commercialized through its own sales and marketing organization and through collaborations with external partners.
===Financial Performance of Regeneron===

Regeneron has achieved strong [[Financial Performance|financial performance]] in recent years. In 2020, Regeneron reported total revenues of $7.3 billion, an increase of 17% compared to 2019. Regeneron’s [[Net Income|net income]] for 2020 was $2.2 billion, an increase of 24% compared to 2019. Regeneron’s total assets as of December 31, 2020 were $20.3 billion, an increase of 11% compared to 2019.
===Conclusion===

Regeneron is a biopharmaceutical company that specializes in the development, manufacture, and commercialization of medicines for the treatment of serious medical conditions. Since its founding in 1988, Regeneron has grown to become one of the world’s leading biopharmaceutical companies, with a portfolio of more than 20 appr